nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ALB—chronic obstructive pulmonary disease	0.447	1	CbGaD
Canagliflozin—ALB—Prednisone—chronic obstructive pulmonary disease	0.0523	0.179	CbGbCtD
Canagliflozin—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0515	0.177	CbGbCtD
Canagliflozin—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0348	0.119	CbGbCtD
Canagliflozin—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0332	0.114	CbGbCtD
Canagliflozin—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0296	0.101	CbGbCtD
Canagliflozin—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.029	0.0994	CbGbCtD
Canagliflozin—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0274	0.0939	CbGbCtD
Canagliflozin—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0174	0.0595	CbGbCtD
Canagliflozin—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0164	0.0562	CbGbCtD
Canagliflozin—Diuresis—Aminophylline—chronic obstructive pulmonary disease	0.0068	0.0449	CcSEcCtD
Canagliflozin—Dapagliflozin—CYP1A1—chronic obstructive pulmonary disease	0.00394	0.509	CrCbGaD
Canagliflozin—Dapagliflozin—CYP1A2—chronic obstructive pulmonary disease	0.0038	0.491	CrCbGaD
Canagliflozin—Vulvovaginal candidiasis—Salbutamol—chronic obstructive pulmonary disease	0.00288	0.019	CcSEcCtD
Canagliflozin—Vulvovaginal mycotic infection—Salbutamol—chronic obstructive pulmonary disease	0.00277	0.0183	CcSEcCtD
Canagliflozin—Renal failure acute—Roflumilast—chronic obstructive pulmonary disease	0.00248	0.0164	CcSEcCtD
Canagliflozin—SLC5A1—respiratory system—chronic obstructive pulmonary disease	0.00209	0.251	CbGeAlD
Canagliflozin—Blood potassium increased—Prednisone—chronic obstructive pulmonary disease	0.00209	0.0138	CcSEcCtD
Canagliflozin—Polyuria—Aminophylline—chronic obstructive pulmonary disease	0.00174	0.0115	CcSEcCtD
Canagliflozin—Nocturia—Formoterol—chronic obstructive pulmonary disease	0.00173	0.0114	CcSEcCtD
Canagliflozin—Nocturia—Arformoterol—chronic obstructive pulmonary disease	0.00173	0.0114	CcSEcCtD
Canagliflozin—SLC5A1—bronchus—chronic obstructive pulmonary disease	0.00172	0.207	CbGeAlD
Canagliflozin—Urinary tract infection—Roflumilast—chronic obstructive pulmonary disease	0.00172	0.0114	CcSEcCtD
Canagliflozin—Hyperkalaemia—Arformoterol—chronic obstructive pulmonary disease	0.00158	0.0104	CcSEcCtD
Canagliflozin—Hyperkalaemia—Formoterol—chronic obstructive pulmonary disease	0.00158	0.0104	CcSEcCtD
Canagliflozin—Cystitis noninfective—Arformoterol—chronic obstructive pulmonary disease	0.00157	0.0104	CcSEcCtD
Canagliflozin—Cystitis noninfective—Formoterol—chronic obstructive pulmonary disease	0.00157	0.0104	CcSEcCtD
Canagliflozin—Cystitis—Arformoterol—chronic obstructive pulmonary disease	0.00155	0.0102	CcSEcCtD
Canagliflozin—Cystitis—Formoterol—chronic obstructive pulmonary disease	0.00155	0.0102	CcSEcCtD
Canagliflozin—SLC5A1—trachea—chronic obstructive pulmonary disease	0.00154	0.186	CbGeAlD
Canagliflozin—Bladder pain—Formoterol—chronic obstructive pulmonary disease	0.00145	0.00959	CcSEcCtD
Canagliflozin—Bladder pain—Arformoterol—chronic obstructive pulmonary disease	0.00145	0.00959	CcSEcCtD
Canagliflozin—Malnutrition—Roflumilast—chronic obstructive pulmonary disease	0.00138	0.00913	CcSEcCtD
Canagliflozin—Dehydration—Tiotropium—chronic obstructive pulmonary disease	0.00134	0.00887	CcSEcCtD
Canagliflozin—Diabetes mellitus—Salbutamol—chronic obstructive pulmonary disease	0.00126	0.00836	CcSEcCtD
Canagliflozin—Angioedema—Roflumilast—chronic obstructive pulmonary disease	0.00126	0.00834	CcSEcCtD
Canagliflozin—Thirst—Montelukast—chronic obstructive pulmonary disease	0.0012	0.00792	CcSEcCtD
Canagliflozin—Hypoglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.00119	0.00789	CcSEcCtD
Canagliflozin—Hypoglycaemia—Formoterol—chronic obstructive pulmonary disease	0.00119	0.00789	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.00117	0.00772	CcSEcCtD
Canagliflozin—Hypoglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.00113	0.00745	CcSEcCtD
Canagliflozin—Infection—Roflumilast—chronic obstructive pulmonary disease	0.00112	0.0074	CcSEcCtD
Canagliflozin—SLC5A1—lung—chronic obstructive pulmonary disease	0.00111	0.133	CbGeAlD
Canagliflozin—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00111	0.00731	CcSEcCtD
Canagliflozin—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.00109	0.00724	CcSEcCtD
Canagliflozin—Multiple fractures—Prednisone—chronic obstructive pulmonary disease	0.00109	0.00718	CcSEcCtD
Canagliflozin—Fracture—Prednisone—chronic obstructive pulmonary disease	0.00109	0.00718	CcSEcCtD
Canagliflozin—Dehydration—Arformoterol—chronic obstructive pulmonary disease	0.00108	0.00716	CcSEcCtD
Canagliflozin—Dehydration—Formoterol—chronic obstructive pulmonary disease	0.00108	0.00716	CcSEcCtD
Canagliflozin—Urinary tract infection—Tiotropium—chronic obstructive pulmonary disease	0.00108	0.00714	CcSEcCtD
Canagliflozin—UGT2B4—lung—chronic obstructive pulmonary disease	0.00102	0.123	CbGeAlD
Canagliflozin—Urinary tract disorder—Tiotropium—chronic obstructive pulmonary disease	0.000985	0.00652	CcSEcCtD
Canagliflozin—Urethral disorder—Tiotropium—chronic obstructive pulmonary disease	0.000978	0.00647	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.000973	0.00643	CcSEcCtD
Canagliflozin—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.000972	0.00643	CcSEcCtD
Canagliflozin—Pancreatitis—Montelukast—chronic obstructive pulmonary disease	0.000966	0.00639	CcSEcCtD
Canagliflozin—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.000964	0.00637	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.000922	0.00609	CcSEcCtD
Canagliflozin—Angiopathy—Tiotropium—chronic obstructive pulmonary disease	0.000905	0.00599	CcSEcCtD
Canagliflozin—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.000895	0.00592	CcSEcCtD
Canagliflozin—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.000891	0.00589	CcSEcCtD
Canagliflozin—Urinary tract infection—Formoterol—chronic obstructive pulmonary disease	0.000872	0.00577	CcSEcCtD
Canagliflozin—Urinary tract infection—Arformoterol—chronic obstructive pulmonary disease	0.000872	0.00577	CcSEcCtD
Canagliflozin—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.000869	0.00574	CcSEcCtD
Canagliflozin—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.00083	0.00549	CcSEcCtD
Canagliflozin—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000823	0.00544	CcSEcCtD
Canagliflozin—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000809	0.00535	CcSEcCtD
Canagliflozin—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.000798	0.00528	CcSEcCtD
Canagliflozin—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.000795	0.00526	CcSEcCtD
Canagliflozin—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.000795	0.00526	CcSEcCtD
Canagliflozin—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.000794	0.00525	CcSEcCtD
Canagliflozin—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.000789	0.00522	CcSEcCtD
Canagliflozin—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.000789	0.00522	CcSEcCtD
Canagliflozin—Syncope—Tiotropium—chronic obstructive pulmonary disease	0.000779	0.00515	CcSEcCtD
Canagliflozin—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.000779	0.00515	CcSEcCtD
Canagliflozin—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.000773	0.00511	CcSEcCtD
Canagliflozin—Loss of consciousness—Tiotropium—chronic obstructive pulmonary disease	0.000763	0.00505	CcSEcCtD
Canagliflozin—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.000751	0.00496	CcSEcCtD
Canagliflozin—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000747	0.00494	CcSEcCtD
Canagliflozin—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000745	0.00493	CcSEcCtD
Canagliflozin—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000745	0.00493	CcSEcCtD
Canagliflozin—Shock—Aminophylline—chronic obstructive pulmonary disease	0.00074	0.00489	CcSEcCtD
Canagliflozin—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000737	0.00487	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000734	0.00486	CcSEcCtD
Canagliflozin—Diabetes mellitus—Prednisolone—chronic obstructive pulmonary disease	0.000725	0.00479	CcSEcCtD
Canagliflozin—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000723	0.00478	CcSEcCtD
Canagliflozin—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000711	0.0047	CcSEcCtD
Canagliflozin—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00071	0.0047	CcSEcCtD
Canagliflozin—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000704	0.00466	CcSEcCtD
Canagliflozin—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000702	0.00464	CcSEcCtD
Canagliflozin—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000701	0.00463	CcSEcCtD
Canagliflozin—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000701	0.00463	CcSEcCtD
Canagliflozin—Shock—Tiotropium—chronic obstructive pulmonary disease	0.000697	0.00461	CcSEcCtD
Canagliflozin—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000695	0.0046	CcSEcCtD
Canagliflozin—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.00069	0.00456	CcSEcCtD
Canagliflozin—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000689	0.00455	CcSEcCtD
Canagliflozin—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00067	0.00443	CcSEcCtD
Canagliflozin—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000662	0.00438	CcSEcCtD
Canagliflozin—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000641	0.00424	CcSEcCtD
Canagliflozin—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000641	0.00424	CcSEcCtD
Canagliflozin—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000627	0.00415	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000615	0.00406	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000612	0.00405	CcSEcCtD
Canagliflozin—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000606	0.00401	CcSEcCtD
Canagliflozin—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000605	0.004	CcSEcCtD
Canagliflozin—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000597	0.00395	CcSEcCtD
Canagliflozin—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000595	0.00393	CcSEcCtD
Canagliflozin—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000594	0.00393	CcSEcCtD
Canagliflozin—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000594	0.00392	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000593	0.00392	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000593	0.00392	CcSEcCtD
Canagliflozin—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000584	0.00386	CcSEcCtD
Canagliflozin—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000584	0.00386	CcSEcCtD
Canagliflozin—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000582	0.00385	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000581	0.00384	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00058	0.00383	CcSEcCtD
Canagliflozin—Infection—Formoterol—chronic obstructive pulmonary disease	0.000568	0.00376	CcSEcCtD
Canagliflozin—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000568	0.00376	CcSEcCtD
Canagliflozin—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000563	0.00372	CcSEcCtD
Canagliflozin—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000561	0.00371	CcSEcCtD
Canagliflozin—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000561	0.00371	CcSEcCtD
Canagliflozin—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00056	0.00371	CcSEcCtD
Canagliflozin—Infection—Montelukast—chronic obstructive pulmonary disease	0.000557	0.00368	CcSEcCtD
Canagliflozin—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000556	0.00367	CcSEcCtD
Canagliflozin—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000556	0.00367	CcSEcCtD
Canagliflozin—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000554	0.00366	CcSEcCtD
Canagliflozin—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000551	0.00364	CcSEcCtD
Canagliflozin—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00055	0.00363	CcSEcCtD
Canagliflozin—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000544	0.0036	CcSEcCtD
Canagliflozin—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000537	0.00355	CcSEcCtD
Canagliflozin—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000535	0.00353	CcSEcCtD
Canagliflozin—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000535	0.00353	CcSEcCtD
Canagliflozin—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000534	0.00353	CcSEcCtD
Canagliflozin—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000532	0.00352	CcSEcCtD
Canagliflozin—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000531	0.00351	CcSEcCtD
Canagliflozin—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00053	0.0035	CcSEcCtD
Canagliflozin—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000527	0.00348	CcSEcCtD
Canagliflozin—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000525	0.00347	CcSEcCtD
Canagliflozin—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000522	0.00345	CcSEcCtD
Canagliflozin—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000505	0.00334	CcSEcCtD
Canagliflozin—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000502	0.00332	CcSEcCtD
Canagliflozin—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000497	0.00329	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000494	0.00327	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000494	0.00327	CcSEcCtD
Canagliflozin—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000493	0.00326	CcSEcCtD
Canagliflozin—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000493	0.00326	CcSEcCtD
Canagliflozin—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000489	0.00323	CcSEcCtD
Canagliflozin—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000489	0.00323	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000484	0.0032	CcSEcCtD
Canagliflozin—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000483	0.00319	CcSEcCtD
Canagliflozin—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000474	0.00313	CcSEcCtD
Canagliflozin—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000474	0.00313	CcSEcCtD
Canagliflozin—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000469	0.0031	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000468	0.00309	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000468	0.00309	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000466	0.00308	CcSEcCtD
Canagliflozin—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000466	0.00308	CcSEcCtD
Canagliflozin—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000462	0.00305	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000458	0.00303	CcSEcCtD
Canagliflozin—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000454	0.00301	CcSEcCtD
Canagliflozin—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000454	0.00301	CcSEcCtD
Canagliflozin—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000452	0.00299	CcSEcCtD
Canagliflozin—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000452	0.00299	CcSEcCtD
Canagliflozin—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000447	0.00296	CcSEcCtD
Canagliflozin—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000447	0.00295	CcSEcCtD
Canagliflozin—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000446	0.00295	CcSEcCtD
Canagliflozin—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000445	0.00294	CcSEcCtD
Canagliflozin—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000443	0.00293	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000442	0.00292	CcSEcCtD
Canagliflozin—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000429	0.00284	CcSEcCtD
Canagliflozin—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000427	0.00282	CcSEcCtD
Canagliflozin—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000421	0.00279	CcSEcCtD
Canagliflozin—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000421	0.00279	CcSEcCtD
Canagliflozin—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000421	0.00278	CcSEcCtD
Canagliflozin—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000413	0.00273	CcSEcCtD
Canagliflozin—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00041	0.00271	CcSEcCtD
Canagliflozin—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00041	0.00271	CcSEcCtD
Canagliflozin—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000405	0.00268	CcSEcCtD
Canagliflozin—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000405	0.00268	CcSEcCtD
Canagliflozin—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000402	0.00266	CcSEcCtD
Canagliflozin—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000398	0.00263	CcSEcCtD
Canagliflozin—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000396	0.00262	CcSEcCtD
Canagliflozin—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000388	0.00257	CcSEcCtD
Canagliflozin—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000388	0.00256	CcSEcCtD
Canagliflozin—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000382	0.00253	CcSEcCtD
Canagliflozin—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.00038	0.00251	CcSEcCtD
Canagliflozin—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000378	0.0025	CcSEcCtD
Canagliflozin—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000378	0.0025	CcSEcCtD
Canagliflozin—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000371	0.00245	CcSEcCtD
Canagliflozin—ORM1—lung—chronic obstructive pulmonary disease	0.000368	0.0442	CbGeAlD
Canagliflozin—Rash—Formoterol—chronic obstructive pulmonary disease	0.000361	0.00239	CcSEcCtD
Canagliflozin—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000361	0.00239	CcSEcCtD
Canagliflozin—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00036	0.00238	CcSEcCtD
Canagliflozin—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00036	0.00238	CcSEcCtD
Canagliflozin—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000357	0.00236	CcSEcCtD
Canagliflozin—Rash—Montelukast—chronic obstructive pulmonary disease	0.000353	0.00234	CcSEcCtD
Canagliflozin—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000353	0.00233	CcSEcCtD
Canagliflozin—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000347	0.00229	CcSEcCtD
Canagliflozin—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000341	0.00225	CcSEcCtD
Canagliflozin—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.00034	0.00225	CcSEcCtD
Canagliflozin—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00034	0.00225	CcSEcCtD
Canagliflozin—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00034	0.00225	CcSEcCtD
Canagliflozin—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00034	0.00225	CcSEcCtD
Canagliflozin—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000334	0.00221	CcSEcCtD
Canagliflozin—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000333	0.0022	CcSEcCtD
Canagliflozin—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000329	0.00217	CcSEcCtD
Canagliflozin—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000321	0.00212	CcSEcCtD
Canagliflozin—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000305	0.00202	CcSEcCtD
Canagliflozin—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000294	0.00314	CbGpPWpGaD
Canagliflozin—SLC5A1—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.000294	0.00314	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.000294	0.00314	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	0.000293	0.00312	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	0.000293	0.00312	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.00029	0.00309	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000289	0.00308	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000289	0.00308	CbGpPWpGaD
Canagliflozin—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000288	0.0019	CcSEcCtD
Canagliflozin—UGT1A9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000283	0.00303	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—SERPINA1—chronic obstructive pulmonary disease	0.000282	0.00301	CbGpPWpGaD
Canagliflozin—UGT1A9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.00028	0.00299	CbGpPWpGaD
Canagliflozin—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000276	0.00182	CcSEcCtD
Canagliflozin—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000276	0.00182	CcSEcCtD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	0.000272	0.00291	CbGpPWpGaD
Canagliflozin—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000271	0.00289	CbGpPWpGaD
Canagliflozin—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00026	0.00278	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—MPO—chronic obstructive pulmonary disease	0.000258	0.00276	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—TGFB2—chronic obstructive pulmonary disease	0.000257	0.00274	CbGpPWpGaD
Canagliflozin—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000252	0.00167	CcSEcCtD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000248	0.00264	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000248	0.00264	CbGpPWpGaD
Canagliflozin—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000247	0.00164	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.000247	0.00264	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—chronic obstructive pulmonary disease	0.000247	0.00263	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000246	0.00263	CbGpPWpGaD
Canagliflozin—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000246	0.00163	CcSEcCtD
Canagliflozin—UGT1A9—PPARA activates gene expression—CYP1A1—chronic obstructive pulmonary disease	0.000245	0.00261	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—TGFB2—chronic obstructive pulmonary disease	0.000244	0.00261	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000244	0.0026	CbGpPWpGaD
Canagliflozin—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000242	0.0016	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—GC—chronic obstructive pulmonary disease	0.00024	0.00256	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CYP1A1—chronic obstructive pulmonary disease	0.00024	0.00256	CbGpPWpGaD
Canagliflozin—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000239	0.00158	CcSEcCtD
Canagliflozin—UGT1A9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000236	0.00252	CbGpPWpGaD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000233	0.00154	CcSEcCtD
Canagliflozin—UGT1A9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000232	0.00248	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—RAPGEF3—chronic obstructive pulmonary disease	0.000229	0.00244	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000228	0.00151	CcSEcCtD
Canagliflozin—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.000227	0.00243	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000225	0.0024	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000224	0.00239	CbGpPWpGaD
Canagliflozin—Infection—Prednisone—chronic obstructive pulmonary disease	0.000224	0.00148	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000223	0.00238	CbGpPWpGaD
Canagliflozin—Shock—Prednisone—chronic obstructive pulmonary disease	0.000222	0.00146	CcSEcCtD
Canagliflozin—UGT1A9—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000221	0.00236	CbGpPWpGaD
Canagliflozin—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000221	0.00146	CcSEcCtD
Canagliflozin—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000219	0.00145	CcSEcCtD
Canagliflozin—ABCC2—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000219	0.00233	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000216	0.0023	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	0.000211	0.00226	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—CRP—chronic obstructive pulmonary disease	0.00021	0.00224	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	0.000207	0.00221	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000206	0.0022	CbGpPWpGaD
Canagliflozin—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000205	0.00135	CcSEcCtD
Canagliflozin—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000205	0.0246	CbGeAlD
Canagliflozin—ABCC2—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000201	0.00214	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000199	0.00213	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	0.000197	0.00211	CbGpPWpGaD
Canagliflozin—UGT1A9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000196	0.0021	CbGpPWpGaD
Canagliflozin—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000195	0.00129	CcSEcCtD
Canagliflozin—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000195	0.00129	CcSEcCtD
Canagliflozin—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000194	0.00128	CcSEcCtD
Canagliflozin—UGT1A9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000194	0.00207	CbGpPWpGaD
Canagliflozin—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000193	0.00127	CcSEcCtD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	0.000191	0.00204	CbGpPWpGaD
Canagliflozin—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000191	0.00204	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000189	0.00202	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000184	0.00122	CcSEcCtD
Canagliflozin—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000184	0.00122	CcSEcCtD
Canagliflozin—UGT1A9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000181	0.00193	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	0.00018	0.00193	CbGpPWpGaD
Canagliflozin—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000179	0.00118	CcSEcCtD
Canagliflozin—UGT1A9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000178	0.0019	CbGpPWpGaD
Canagliflozin—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000178	0.00118	CcSEcCtD
Canagliflozin—UGT1A9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000171	0.00183	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—CRP—chronic obstructive pulmonary disease	0.000171	0.00183	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HDAC2—chronic obstructive pulmonary disease	0.00017	0.00182	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HDAC2—chronic obstructive pulmonary disease	0.00017	0.00182	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.00017	0.00181	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.00017	0.00181	CbGpPWpGaD
Canagliflozin—UGT1A9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000169	0.0018	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000168	0.0018	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000168	0.00179	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000168	0.00179	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000166	0.0011	CcSEcCtD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000165	0.00177	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000165	0.00176	CbGpPWpGaD
Canagliflozin—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000162	0.00107	CcSEcCtD
Canagliflozin—ALB—Vitamin B12 Metabolism—SERPINE1—chronic obstructive pulmonary disease	0.000161	0.00172	CbGpPWpGaD
Canagliflozin—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000159	0.00105	CcSEcCtD
Canagliflozin—SLC5A2—Disease—KL—chronic obstructive pulmonary disease	0.000158	0.00169	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—KL—chronic obstructive pulmonary disease	0.000158	0.00169	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000158	0.00169	CbGpPWpGaD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000155	0.00165	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.000154	0.00165	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000153	0.00163	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000153	0.00163	CbGpPWpGaD
Canagliflozin—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000153	0.00163	CbGpPWpGaD
Canagliflozin—ABCB1—trachea—chronic obstructive pulmonary disease	0.000151	0.0182	CbGeAlD
Canagliflozin—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000149	0.000984	CcSEcCtD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	0.000149	0.00159	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	0.000149	0.00159	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000147	0.00157	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	0.000147	0.00157	CbGpPWpGaD
Canagliflozin—Rash—Prednisone—chronic obstructive pulmonary disease	0.000142	0.000939	CcSEcCtD
Canagliflozin—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000142	0.000938	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000141	0.00151	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000141	0.00151	CbGpPWpGaD
Canagliflozin—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000139	0.00148	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—APIP—chronic obstructive pulmonary disease	0.000138	0.00147	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	0.000137	0.00146	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	0.000136	0.00145	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SERPINE2—chronic obstructive pulmonary disease	0.000135	0.00144	CbGpPWpGaD
Canagliflozin—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000884	CcSEcCtD
Canagliflozin—ALB—Folate Metabolism—SERPINE1—chronic obstructive pulmonary disease	0.000131	0.0014	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SERPINA1—chronic obstructive pulmonary disease	0.000131	0.0014	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IL1B—chronic obstructive pulmonary disease	0.000131	0.0014	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.000131	0.0014	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000129	0.00138	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000125	0.00134	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—ERBB3—chronic obstructive pulmonary disease	0.000119	0.00127	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—ERBB3—chronic obstructive pulmonary disease	0.000119	0.00127	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000118	0.00126	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	0.000118	0.00126	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.000118	0.00126	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.000118	0.00126	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	0.000116	0.00124	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	0.000116	0.00124	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	0.000115	0.00123	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB2—chronic obstructive pulmonary disease	0.000114	0.00122	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—SERPINE1—chronic obstructive pulmonary disease	0.000113	0.0012	CbGpPWpGaD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000112	0.0012	CbGpPWpGaD
Canagliflozin—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000111	0.00118	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000109	0.00116	CbGpPWpGaD
Canagliflozin—ABCB1—lung—chronic obstructive pulmonary disease	0.000109	0.0131	CbGeAlD
Canagliflozin—SLC5A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	0.000108	0.00115	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	0.000108	0.00115	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—chronic obstructive pulmonary disease	0.000107	0.00115	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL1B—chronic obstructive pulmonary disease	0.000107	0.00114	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	0.000104	0.00111	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000104	0.00111	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000102	0.00109	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000102	0.00109	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NOS2—chronic obstructive pulmonary disease	9.89e-05	0.00106	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NOS2—chronic obstructive pulmonary disease	9.89e-05	0.00106	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	9.82e-05	0.00105	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—TNF—chronic obstructive pulmonary disease	9.52e-05	0.00102	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.12e-05	0.000974	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	9.11e-05	0.000973	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.08e-05	0.00097	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	9.05e-05	0.000966	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.95e-05	0.000956	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GC—chronic obstructive pulmonary disease	8.87e-05	0.000948	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	8.48e-05	0.000905	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	8.44e-05	0.000901	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	8.39e-05	0.000896	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.34e-05	0.000891	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—SERPINE1—chronic obstructive pulmonary disease	8.33e-05	0.00089	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—SERPINE1—chronic obstructive pulmonary disease	8.33e-05	0.00089	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.25e-05	0.000881	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	8.19e-05	0.000874	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	8.1e-05	0.000865	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	8.01e-05	0.000856	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NOS3—chronic obstructive pulmonary disease	7.95e-05	0.000849	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NOS3—chronic obstructive pulmonary disease	7.95e-05	0.000849	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.92e-05	0.000846	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	7.92e-05	0.000845	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.91e-05	0.000845	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—VEGFA—chronic obstructive pulmonary disease	7.75e-05	0.000827	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TNF—chronic obstructive pulmonary disease	7.74e-05	0.000827	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IL6—chronic obstructive pulmonary disease	7.68e-05	0.00082	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—chronic obstructive pulmonary disease	7.38e-05	0.000788	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APIP—chronic obstructive pulmonary disease	7.21e-05	0.00077	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—TGFB1—chronic obstructive pulmonary disease	7.11e-05	0.000759	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ALB—chronic obstructive pulmonary disease	6.96e-05	0.000744	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ALB—chronic obstructive pulmonary disease	6.96e-05	0.000744	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	6.9e-05	0.000737	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	6.85e-05	0.000732	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—chronic obstructive pulmonary disease	6.83e-05	0.000729	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—chronic obstructive pulmonary disease	6.77e-05	0.000723	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	6.77e-05	0.000723	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—NOS3—chronic obstructive pulmonary disease	6.66e-05	0.000711	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—NOS3—chronic obstructive pulmonary disease	6.66e-05	0.000711	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.66e-05	0.000711	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	6.57e-05	0.000702	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.57e-05	0.000701	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	6.32e-05	0.000675	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	6.29e-05	0.000672	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL6—chronic obstructive pulmonary disease	6.25e-05	0.000667	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	6.15e-05	0.000657	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	5.87e-05	0.000627	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB2—chronic obstructive pulmonary disease	5.87e-05	0.000626	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.55e-05	0.000593	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.48e-05	0.000585	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ALB—chronic obstructive pulmonary disease	5.38e-05	0.000574	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—HDAC2—chronic obstructive pulmonary disease	5.26e-05	0.000562	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TGFB1—chronic obstructive pulmonary disease	5.26e-05	0.000562	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TGFB1—chronic obstructive pulmonary disease	5.26e-05	0.000562	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EGFR—chronic obstructive pulmonary disease	5.16e-05	0.000551	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EGFR—chronic obstructive pulmonary disease	5.16e-05	0.000551	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—NOS3—chronic obstructive pulmonary disease	5.14e-05	0.000549	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	5.14e-05	0.000549	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.1e-05	0.000545	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.03e-05	0.000538	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	4.99e-05	0.000533	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	4.96e-05	0.00053	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.85e-05	0.000518	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.84e-05	0.000517	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GCLC—chronic obstructive pulmonary disease	4.79e-05	0.000512	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.78e-05	0.00051	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.77e-05	0.00051	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PLAUR—chronic obstructive pulmonary disease	4.74e-05	0.000507	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	4.74e-05	0.000506	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GC—chronic obstructive pulmonary disease	4.65e-05	0.000496	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	4.47e-05	0.000477	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CTGF—chronic obstructive pulmonary disease	4.37e-05	0.000467	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.32e-05	0.000461	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.18e-05	0.000447	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	4.15e-05	0.000443	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	4.07e-05	0.000435	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.03e-05	0.00043	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6—chronic obstructive pulmonary disease	3.96e-05	0.000423	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6—chronic obstructive pulmonary disease	3.96e-05	0.000423	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	3.89e-05	0.000416	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.78e-05	0.000404	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.7e-05	0.000396	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	3.44e-05	0.000368	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	3.44e-05	0.000367	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MMP1—chronic obstructive pulmonary disease	3.39e-05	0.000362	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	3.38e-05	0.000361	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.36e-05	0.000359	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PLAU—chronic obstructive pulmonary disease	3.33e-05	0.000355	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.31e-05	0.000354	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.25e-05	0.000347	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	3.15e-05	0.000337	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	3.1e-05	0.000332	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.09e-05	0.00033	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS2—chronic obstructive pulmonary disease	3.06e-05	0.000326	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	3.04e-05	0.000325	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.93e-05	0.000313	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	2.9e-05	0.00031	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.58e-05	0.000275	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	2.57e-05	0.000275	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	2.56e-05	0.000273	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.54e-05	0.000271	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GCLC—chronic obstructive pulmonary disease	2.51e-05	0.000268	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	2.51e-05	0.000268	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—NOS3—chronic obstructive pulmonary disease	2.46e-05	0.000262	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.33e-05	0.000249	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CTGF—chronic obstructive pulmonary disease	2.29e-05	0.000244	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.22e-05	0.000237	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	2.2e-05	0.000235	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.11e-05	0.000225	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	2.01e-05	0.000214	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALB—chronic obstructive pulmonary disease	1.99e-05	0.000213	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.95e-05	0.000208	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—NOS3—chronic obstructive pulmonary disease	1.9e-05	0.000203	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.85e-05	0.000197	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.77e-05	0.000189	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.76e-05	0.000188	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.74e-05	0.000185	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.63e-05	0.000174	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.62e-05	0.000173	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.54e-05	0.000165	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.53e-05	0.000164	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.52e-05	0.000162	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.42e-05	0.000151	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.37e-05	0.000146	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.35e-05	0.000145	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.34e-05	0.000143	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—chronic obstructive pulmonary disease	1.34e-05	0.000143	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.24e-05	0.000132	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.14e-05	0.000122	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—NOS3—chronic obstructive pulmonary disease	9.97e-06	0.000106	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.5e-06	0.000101	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.37e-06	0.0001	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	9.13e-06	9.75e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	8.73e-06	9.32e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.73e-06	9.32e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.27e-06	8.84e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	5.62e-06	6.01e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	5.38e-06	5.75e-05	CbGpPWpGaD
